Guardant Health Inc

GH is in a robust Stage 2 advance with a parabolic acceleration above rising EMAs, anchoring bullish medium- and long-term biases. However, extreme overbought conditions and an exhaustion candle near the peak suggest near-term timing is unfavorable. Execution should be deferred until a pullback into the rising EMA 9/21 support zone or prior consolidation range confirms renewed buying interest.

• ↑Q1 2026 revenue reached $302M, a 48% YoY increase
• ↑SHIELD revenue jumped to $42M from $6M YoY on 44,000 tests
• ↓Q1 free cash flow burn increased to $71M from $67M last year